{"id":"NCT02826603","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis","officialTitle":"A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-22","primaryCompletion":"2018-07-09","completion":"2018-07-09","firstPosted":"2016-07-11","resultsPosted":"2019-07-09","lastUpdate":"2019-07-09"},"enrollment":1114,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Secukinumab","otherNames":[]},{"type":"DRUG","name":"Ustekinumab","otherNames":[]}],"arms":[{"label":"Secukinumab","type":"EXPERIMENTAL"},{"label":"Ustekinumab","type":"ACTIVE_COMPARATOR"}],"summary":"Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Secukinumab 300mg (2 x 150 mg)","deltaMin":366,"sd":null},{"arm":"Ustekinumab 2 x 45mg or 90mg","deltaMin":265,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":154,"countries":["United States","Canada","Czechia","Guatemala","Hungary","Iceland","Malaysia","Poland","Slovakia","South Korea","Vietnam"]},"refs":{"pmids":["36334236","34870789","32365251","30334147"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":550},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache","Diarrhoea","Sinusitis"]}}